Daxor Corporation Receives National Institutes of Health (NIH) Funding Notification for Landmark Multi-Center Heart Failure T...
06 Maio 2021 - 09:30AM
Daxor Corporation (NYSE MKT: DXR), the global leader in blood
volume measurement technology, today announces the initiation of a
multi-center clinical trial with two Veterans Affairs Medical
Centers to evaluate Blood Volume Analysis guided management of
acute decompensated heart failure (ADHF) utilizing the BVA-100
blood test.
Over 6 million Americans suffer from heart
failure, one of the most prevalent and deadly diseases leading to
nearly 1 million deaths and 1 million hospitalizations annually.
The study’s primary objective is to determine the benefit of
goal-directed care guided by Daxor’s blood volume measurement
system, in addition to usual care, resulting in more appropriate
treatment and consistent achievement of optimal blood volume.
“We are gratified to have received notification
of intent to fund the study from the NIH so that work may commence
immediately with the VA system for this landmark prospective study.
Past published data has shown BVA-100 guided care has led to
reductions in patient mortality of over 82% and 56% for
readmissions. This grant and potential subsequent funding stages
will result in the highest quality of clinical data driving
adoption of Daxor’s unique technology broadly, as well as
validation of Daxor’s patent-pending clinical guidance system”,
said Michael Feldschuh, CEO and President of Daxor. “High rates of
heart failure rehospitalization and mortality and high treatment
costs have persisted for decades despite advances in care. The
BVA-100 blood test provides a simple, inexpensive, and objective
measurement of volume status and composition. This precision
enables individualization of treatment and significantly better
outcomes for patients.”
Dr. Jacob Joseph, Director of Heart Failure
Program at VA Boston Healthcare System, Director of Clinical
Research Partnerships and Innovations at the Massachusetts Veterans
Epidemiology Research and Information Center-Division of Population
Health & Genomic Medicine, and Associate Professor of Medicine
at Harvard Medical School, will serve as the study’s Principal
Investigator. “Optimal fluid stewardship is one of the most
important and challenging goals of heart failure treatment,” Dr.
Joseph added. “The purpose of this study is to determine if Blood
Volume Analysis provides important information for improving care
in this vulnerable population.”
“The timing of this study converges with our
planned next-generation analyzer product development schedule,
which includes production of both nuclear and novel
fluorescing-based point-of-care testing options over the next
year,” said Jonathan Feldschuh, Chief Scientific Officer of Daxor.
“Our next-generation system promises to be even faster, easier, and
expand use of our test into more clinical settings for more
indications.”
For more information visit: ClinicalTrials.gov, Identifier:
NCT04855097.
About Daxor Corporation Daxor
Corporation (NYSE: DXR) is the global leader in blood volume
measurement technology focused on blood volume testing innovation
(organized as an investment company with fully-owned innovative
medical instrumentation and biotechnology operations). We developed
and market the BVA-100® (Blood Volume Analyzer), the first
diagnostic blood test cleared by the FDA to provide safe, accurate,
objective quantification of blood volume status and composition
compared to patient-specific norms. The BVA technology enhances
hospital performance metrics in a broad range of surgical and
medical conditions, including heart failure and critical care, by
informing treatment strategies, resulting in significantly improved
multiple measures of patient outcomes. Daxor's mission is to
advance healthcare by enabling optimal fluid management with blood
volume analysis. Daxor’s vision is optimal blood volume for all.
For more information, please visit our website at Daxor.com.
Forward-Looking
StatementsCertain statements in this release may include
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995, including without
limitation, statements regarding the impact of hiring sales staff
and expansion of our distribution channels. Forward-looking
statements are predictions, projections and other statements about
future events that are based on current expectations and
assumptions and, as a result, are subject to risks and
uncertainties. Many factors could cause actual future events to
differ materially from the forward-looking statements in this
release, including, without limitation, those risk associated with
our post-market clinical data collection activities, benefits of
our products to patients, our expectations with respect to product
development and commercialization efforts, our ability to increase
market and physician acceptance of our products, potentially
competitive product offerings, intellectual property protection,
FDA regulatory actions, our ability to integrate acquired
businesses, our expectations regarding anticipated synergies with
and benefits from acquired businesses, and additional other risks
and uncertainties described in our filings with the SEC.
Forward-looking statements speak only as of the date when made.
Daxor does not assume any obligation to publicly update or revise
any forward-looking statements, whether as a result of new
information, future events or otherwise.
Investor Relations Contact:Bret
ShapiroSr. Managing Partner, CORE
IR516-222-2560brets@coreir.com
Daxor (AMEX:DXR)
Gráfico Histórico do Ativo
De Fev 2024 até Mar 2024
Daxor (AMEX:DXR)
Gráfico Histórico do Ativo
De Mar 2023 até Mar 2024